European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

Development, dIagnostic and prevention of gender-related Somatic and mental COmorbitiEs in iRritable bowel syndrome In Europe

Descrizione del progetto

Diagnosi, prevenzione e trattamento migliori

Oltre 60 milioni di europei soffrono di ansia e depressione o fibromialgia e sindrome da affaticamento cronico. Queste condizioni (comorbilità) sono comuni nella sindrome dell’intestino irritabile (IBS, Irritable Bowel Syndrome), un disturbo cronico che colpisce soprattutto le donne. L’IBS incide sulla qualità della vita dei pazienti. Ma l’origine e i meccanismi delle comorbilità dell’IBS rimangono inspiegabili, e il trattamento è costoso e insoddisfacente. Il progetto DISCOvERIE, finanziato dall’UE, intende spiegare i meccanismi causali delle comorbilità dell’IBS, identificandoli come entità clinica distinta per consentire un significativo miglioramento dei metodi di trattamento. Le conoscenze psicopatologiche specifiche delle comorbilità dell’IBS consentiranno la fornitura di biomarcatori prognostici e la creazione di guide e protocolli per nuove unità ospedaliere speciali che forniscono assistenza personalizzata.

Obiettivo

Mental (anxiety and depression) and non-mental (fibromyalgia and chronic fatigue syndrome) comorbidities are highly prevalent in irritable bowel syndrome (IBS), with over 60 million Europeans affected, mostly women, by devastating manifestations, impaired treatment and quality of life. Estimated costs are €43 billion/year for IBS, mostly derived from comorbid IBS. Our hypothesis is that comorbid IBS represents a distinct clinical entity, arising from distorted brain-gut communication with a unique, specific, but undefined pathophysiological origin, differing from IBS alone. DISCOvERIE was created to advance the understanding of its causative mechanisms. Identification, validation and comprehension of these mechanisms will help stratify these patients into distinct clinical phenotypes, improving disease management, increasing quality of life and reducing socioeconomic costs. In particular, we will deliver specific comorbid-IBS physiopathological knowledge as clinical guides and protocols for newly created, hospital-based, transversal and multidisciplinary units for implementing personalized management and wellbeing of European citizens and to position Europe as a global leader in comorbid IBS personalised medicine. We will also deliver prognostic and therapeutic biomarkers and patents, technological innovation via e-health tools for personalized assessment of clinical/nutritional/physical activity and disseminate new knowledge widely. Impact will be assessed by recording media presence, scientific publications and by monitoring health-related quality of life of patients and promoting cost-effective care. To this end we have created a user board involving patient associations, clinical specialists, European healthcare experts, large pharma and SMEs representatives. We will also promote the creation of a European Reference Network for comorbid IBS involving healthcare providers across Europe.

Invito a presentare proposte

H2020-SC1-BHC-2018-2020

Vedi altri progetti per questo bando

Bando secondario

H2020-SC1-2019-Two-Stage-RTD

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA
Contribution nette de l'UE
€ 1 148 684,84
Indirizzo
PASSEIG VALL D HEBRON 119-129 EDIFICIO DE RECERCA
08035 Barcelona
Spagna

Mostra sulla mappa

Regione
Este Cataluña Barcelona
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 1 148 684,84

Partecipanti (20)